Humacyte, Inc.

NasdaqGS:HUMA Stock Report

Market Cap: US$580.3m

Humacyte Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:HUMA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 Dec 24BuyUS$20,181Michael ConstantinoIndividual4,600US$4.39
20 Nov 24SellUS$6,606,799Ayabudge LLCCompany1,500,000US$4.44
19 Nov 24BuyUS$7,979Laura NiklasonIndividual1,797US$4.44
10 Sep 24SellUS$2,364,521Ayabudge LLCCompany446,378US$5.42
29 Aug 24BuyUS$7,998Laura NiklasonIndividual1,222US$6.55
29 Aug 24SellUS$5,724,139Ayabudge LLCCompany881,878US$6.71
15 Aug 24BuyUS$19,494Michael ConstantinoIndividual3,100US$6.29
12 Jun 24SellUS$2,520,024Ayabudge LLCCompany348,148US$7.30
11 Jun 24SellUS$2,000,000Ayabudge LLCCompany282,000US$7.09
04 Jun 24BuyUS$14,999Laura NiklasonIndividual2,362US$6.35
03 Jun 24BuyUS$15,109Laura NiklasonIndividual2,050US$7.37
31 May 24SellUS$502,272Heather PrichardIndividual64,566US$9.41
20 May 24BuyUS$50,030Max WallaceIndividual8,005US$6.29
15 May 24BuyUS$667,500Gordon BinderIndividual100,000US$6.78

Insider Trading Volume

Insider Buying: HUMA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of HUMA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies2,879,1242.24%
Individual Insiders11,868,5919.22%
Public Companies18,312,73514.2%
Institutions36,382,25928.3%
General Public59,225,77546%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.2%.

Top Shareholders

Top 25 shareholders own 48.49% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.2%
Fresenius Medical Care AG
18,312,735US$82.6m0%no data
6.95%
Gavril Yushvaev
8,942,078US$40.3m0%no data
5.86%
BlackRock, Inc.
7,539,339US$34.0m5.59%no data
3.93%
The Vanguard Group, Inc.
5,058,689US$22.8m6.96%no data
3.7%
State Street Global Advisors, Inc.
4,764,155US$21.5m66.1%no data
1.59%
Geode Capital Management, LLC
2,040,218US$9.2m9.62%no data
1.41%
Rajiv Shukla
1,814,789US$8.2m0%no data
1.35%
Ayabudge LLC
1,730,884US$7.8m-46.4%no data
0.99%
Millennium Management LLC
1,267,507US$5.7m-20.8%no data
0.98%
Voloridge Investment Management, LLC
1,259,940US$5.7m83.3%0.02%
0.89%
The Niklason Living Trust
1,148,240US$5.2m0%no data
0.83%
Two Sigma Investments, LP
1,068,239US$4.8m-6.46%0.01%
0.66%
Woodline Partners LP
848,534US$3.8m0%0.03%
0.63%
Northern Trust Global Investments
808,486US$3.6m41.2%no data
0.58%
Goldman Sachs Group, Investment Banking and Securities Investments
751,465US$3.4m12.8%no data
0.56%
Charles Schwab Investment Management, Inc.
721,318US$3.3m10.2%no data
0.45%
Marshall Wace LLP
584,562US$2.6m26.1%no data
0.43%
Susquehanna International Group, LLP, Asset Management Arm
556,970US$2.5m4,600%no data
0.42%
Morgan Stanley, Investment Banking and Brokerage Investments
540,508US$2.4m208%no data
0.42%
Monashee Investment Management, LLC
535,000US$2.4m91.1%0.21%
0.4%
LPL Financial Corporation, Asset Management Arm
511,992US$2.3m10.5%no data
0.4%
Brady Dougan
510,161US$2.3m0%no data
0.29%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
377,297US$1.7m-69.2%no data
0.29%
Private Advisor Group, LLC
373,110US$1.7m1.78%0.01%
0.25%
Leap Investments LP
324,800US$1.5m104%0.03%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 21:27
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Humacyte, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Michael GormanBTIG
Kristen KluskaCantor Fitzgerald & Co.